There are 2789 resources available
704P - Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA
Presenter: Alicia Morgans
Session: ePoster Display
705P - Systematic literature review (SLR) and network meta-analysis (NMA) of first-line (1L) therapies for locally advanced/metastatic urothelial carcinoma (la/mUC)
Presenter: Lisa Bloudek
Session: ePoster Display
686P - Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial
Presenter: Laetitia Mauge
Session: ePoster Display
687P - NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab
Presenter: Lucia Carril Ajuria
Session: ePoster Display
688P - Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features
Presenter: Pedro Miguel Coelho Barata
Session: ePoster Display
710P - Comprehensive genomic profiling (CGP) of small cell neuroendocrine carcinoma of the bladder (NEBC)
Presenter: Andrea Necchi
Session: ePoster Display
711P - Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials
Presenter: Cedric Pobel
Session: ePoster Display
712P - Analysis of fibroblast growth factor receptor 3 aberrations in bladder cancer, for enabling personalized and effective therapy based on FGFR inhibitor
Presenter: Roman Sosnowski
Session: ePoster Display
713P - Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial
Presenter: Natacha Naoun
Session: ePoster Display